Literature DB >> 27812727

[Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant].

H-P Sobotta1, T Gösling2.   

Abstract

There are a number of case reports about women undergoing long-term bisphosphonate therapy who have suffered an atypical subtrochanteric or femoral shaft fracture due to an inadequate trauma.The present case reports on a patient who underwent a subtrochanteric femur fracture with the inserted AO femur interlocking nail.

Entities:  

Keywords:  Atypical femoral fracture; Implant fracture; Osteoporosis; Subtrochanteric fracture; Therapy with alendronate

Mesh：

Substances：

Year:  2017        PMID： 27812727     DOI： 10.1007/s00113-016-0270-5

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN： 0177-5537            Impact factor:   1.000


  16 in total

1.  Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group.

Authors:  R P Tonino; P J Meunier; R Emkey; J A Rodriguez-Portales; C J Menkes; R D Wasnich; H G Bone; A C Santora; M Wu; R Desai; P D Ross
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.

Authors:  Ashley V Sloan; Joseph R Martin; Shuo Li; Jiliang Li
Journal:  Bone       Date:  2010-05-16       Impact factor: 4.398

3.  Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

4.  Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Authors:  S-K Goh; K Y Yang; J S B Koh; M K Wong; S Y Chua; D T C Chua; T S Howe
Journal:  J Bone Joint Surg Br       Date:  2007-03

5.  Effect of alendronate in elderly patients after low trauma hip fracture repair.

Authors:  D Cecilia; E Jódar; C Fernández; C Resines; F Hawkins
Journal:  Osteoporos Int       Date:  2008-10-28       Impact factor: 4.507

6.  Low-energy femoral shaft fractures associated with alendronate use.

Authors:  Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich
Journal:  J Orthop Trauma       Date:  2008 May-Jun       Impact factor: 2.512

7.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

8.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

Review 9.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Authors:  R Rizzoli; K Akesson; M Bouxsein; J A Kanis; N Napoli; S Papapoulos; J-Y Reginster; C Cooper
Journal:  Osteoporos Int       Date:  2010-11-18       Impact factor: 4.507

10.  Spontaneous Incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report.

Authors:  Anas Alfahad; Ei Mon Thet; Fawzy Radwan; Joe Sudhakar; Khin Nini; Phaedra Tachtatzis
Journal:  J Med Case Rep       Date:  2012-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.